Consensus Microbot Medical Inc.

Equities

MBOT

US59503A2042

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
1.02 ^USD	-0.97%		-1.92%	-37.80%

06-20	Microbot Medical Inc Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial	CI
06-20	Microbot Medical Inc. announced that it has received $1.762502 million in funding	CI

Evolution of the average Target Price on Microbot Medical Inc.

Price target over the last 5 years

History of analyst recommendation changes

25e51a8151fa8ab3.j7aBZuOCNoAd_Htr8Eh8pFKAXixq7iKDK96fXmAYQKw.4fC3VJr6RrJHjQ4YtyZNkwP5CFYtmFbrY5z4LhhoOeHM_dQUgNRA1XO9Sw~76c25ff0dcded325cdffb2cdecb17ba4

Analyst Recommendations on Microbot Medical Inc.

HC Wainwright Adjusts Microbot Medical's Price Target to $7 From $8, Keeps Buy Rating	04-16	MT
HC Wainwright Adjusts Price Target on Microbot Medical to $8 From $20, Keeps Buy Rating	23-05-09	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.02 USD

Average target price

7 USD

Spread / Average Target

+586.27%

High Price Target

7 USD

Spread / Highest target

+586.27%

Low Price Target

7 USD

Spread / Lowest Target

+586.27%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Microbot Medical Inc.

HC Wainwright

Quarterly revenue - Rate of surprise

Company calendar